Biotalys NV (BTLS)
Euronext Brussels · Belgium · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 1.646 |
|---|---|
| 52-week range | 1.560 – 5.280 |
| Return, 1 month / 3 months | −17.3% / −44.5% |
| Return, 1 year / 3 years | −62.6% / −48.6% |
| Trend | Below its 200-day average |
| RSI (14) | 23 |
| Volatility (1 year) | 69.1% |
| Worst drawdown (1 year) | -68.6% |
| Average daily value traded | 0.04M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Biotalys is an agricultural biotechnology company based in Belgium that develops protein-based biocontrol products for protecting crops. Its products are designed to control pests and fungal diseases in fruits, vegetables and other crops, offering growers alternatives to conventional chemical pesticides. The company works with agricultural producers and the crop protection industry, and its technology is built on antibody-derived proteins that act against specific targets while fitting into established farming practices.
On this site Biotalys NV appears as a stock on the Euronext Brussels (Belgium), code BTLS, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biotalys NV (BTLS) trades on the Euronext Brussels in Belgium. It last closed at EUR 1.646 on 23 October 2026.
Its price-based Market X-Ray is 14 out of 100 (a weak price profile), ranking 103 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 62.6% and over the last three months it fell 44.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 10 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -36.8% | ||
| From 52-week high | -68.6% | ||
| Momentum | 9 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -44.5% | ||
| 6-month return | -26.2% | ||
| 12-month return, skipping the last month | -54.8% | ||
| Stability (higher is calmer) | 8 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 69.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -68.6% | ||
| Liquidity | 38 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.04M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −5.4% |
|---|---|
| 1 month | −17.3% |
| 3 months | −44.5% |
| 6 months | −26.2% |
| 1 year | −62.6% |
| 3 years | −48.6% |
| 5 years | −76.5% |
Signals
| 50-day / 200-day average | 2.108 / 2.605 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.060 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.